Short answer
Medtronic (MDT) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Michael Marinaro appointed President, Medtronic, effective October 14, 2026, expanding oversight to Greater China.
Medtronic 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Michael Marinaro appointed President, Medtronic, effective October 14, 2026, expanding oversight to Greater China
- CEO Geoffrey S. Martha retains chairman and CEO roles, preserving existing top-level leadership structure
- Fiscal 2027 base salary increased to $1,000,000, with target annual incentive unchanged at 100% of salary
- Supplemental long-term incentives valued at approximately $3.25 million, including performance shares, options and restricted stock
- Awards create multiyear retention incentives, with vesting extending through August 2029 and performance measurement through fiscal 2029
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All 12 director nominees re-elected through 2027, with Craig Arnold receiving the highest opposition at 162.4 million votes
- PwC ratified as fiscal 2027 auditor, while Audit Committee retains binding authority over auditor remuneration
- Executive compensation approved on an advisory basis, with 936.3 million votes for and 62.5 million against
- Share issuance authority renewed, preserving Board flexibility for capital raising under Irish law
- Pre-emption opt-out and overseas share-purchase authorization approved, supporting financing flexibility and potential buybacks
Item 7.01 · Regulation FD Disclosure
- MiniMed Group separation completed following settlement of the exchange offer
- Medtronic shareholders’ ownership structure changed through the completed exchange offer
- Strategic separation may sharpen Medtronic’s focus on its remaining medical-device businesses
Item EX-99.1 · Exhibit EX-99.1
- MiniMed separation completed October 15, 2026, creating an independent Nasdaq-listed diabetes company
- Medtronic exchanged its remaining 252,813,348 MiniMed shares through the offer, eliminating its residual ownership
- Exchange offer was 5.4x subscribed, signaling strong demand from Medtronic shareholders for MiniMed shares
- Medtronic now concentrating resources on Cardiovascular, Neuroscience and Surgical portfolios
- Investors should monitor standalone execution, separation benefits and tax treatment, all subject to stated risks
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Medtronic 8-K filings
Get the next MDT 8-K as it lands
Follow MDT for push alerts, or ask the research agent what this filing means.